Unknown

Dataset Information

0

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.


ABSTRACT: Natural killer (NK) cells are an attractive cell-type for adoptive immunotherapy, but challenges in preparation of therapeutic primary NK cells restrict patient accessibility to NK cell immunotherapy. NK-92 is a well-characterized human NK cell line that has demonstrated promising anti-cancer activities in clinical trials. Unlimited proliferation of NK-92 cells provides a consistent supply of cells for the administration and development of NK cell immunotherapy. However, the clinical efficacy of NK-92 cells has not reached its full potential due to reduced immune functions as compared to primary NK cells. Improvements of NK-92 functions currently rely on conventional transgene delivery by mRNA, plasmid and viral vector with limited efficiencies. To enable precise genetic modifications, we have established a robust CRISPR genome engineering platform for NK-92 based on the nucleofection of Cas9 ribonucleoprotein. To demonstrate the versatility of the platform, we have performed cell-based screening of Cas9 guide RNA, multiplex gene knockout of activating and inhibitory receptors, knock-in of a fluorescent gene, and promoter insertion to reactivate endogenous CD16 and DNAM-1. The CRISPR-engineered NK-92 demonstrated markedly enhanced cytotoxicity and could mediate antibody-dependent cellular cytotoxicity against hard to kill cancer cell lines. Our genome editing platform is straightforward and robust for both functional studies and therapeutic engineering of NK-92 cells.

SUBMITTER: Huang RS 

PROVIDER: S-EPMC7256201 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.

Huang Rih-Sheng RS   Shih Hsin-An HA   Lai Min-Chi MC   Chang Yao-Jen YJ   Lin Steven S  

Frontiers in immunology 20200522


Natural killer (NK) cells are an attractive cell-type for adoptive immunotherapy, but challenges in preparation of therapeutic primary NK cells restrict patient accessibility to NK cell immunotherapy. NK-92 is a well-characterized human NK cell line that has demonstrated promising anti-cancer activities in clinical trials. Unlimited proliferation of NK-92 cells provides a consistent supply of cells for the administration and development of NK cell immunotherapy. However, the clinical efficacy of  ...[more]

Similar Datasets

| S-EPMC3969860 | biostudies-literature
| S-EPMC6124898 | biostudies-literature
| S-EPMC5771229 | biostudies-literature
| S-EPMC6141065 | biostudies-literature
| S-EPMC4074098 | biostudies-literature
| S-EPMC4877446 | biostudies-other
| S-EPMC5150520 | biostudies-literature
| S-EPMC4383097 | biostudies-literature
| S-EPMC6859288 | biostudies-literature
| S-EPMC6096830 | biostudies-literature